Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Riedl, JM; Barth, DA; Brueckl, WM; Zeitler, G; Foris, V; Mollnar, S; Stotz, M; Rossmann, CH; Terbuch, A; Balic, M; Niedrist, T; Bertsch, T; Stoeger, H; Pichler, M; Olschewski, H; Absenger, G; Ficker, JH; Gerger, A; Posch, F.
C-Reactive Protein (CRP) Levels in Immune Checkpoint Inhibitor Response and Progression in Advanced Non-Small Cell Lung Cancer: A Bi-Center Study.
Cancers (Basel). 2020; 12(8): Doi: 10.3390/cancers12082319 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Führende Autor*innen der Med Uni Graz

Posch Florian

Riedl Jakob

Co-Autor*innen der Med Uni Graz

Absenger Gudrun

Balic Marija

Barth Dominik Andreas

Foris Vasile

Gerger Armin

Niedrist Tobias

Olschewski Horst

Pichler Martin

Stöger Herbert

Stotz Michael

Terbuch Angelika

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

Biomarkers for predicting response to immune checkpoint inhibitors (ICI) are scarce and often lack external validation. This study provides a comprehensive investigation of pretreatment C-reactive protein (CRP) levels as well as its longitudinal trajectories as a marker of treatment response and disease outcome in patients with advanced non-small cell lung cancer (NSCLC) undergoing immunotherapy with anti PD-1 or anti PD-L1 agents. We performed a retrospective bi-center study to assess the association between baseline CRP levels and anti PD-(L)1 treatment outcomes in the discovery cohort (n = 90), confirm these findings in an external validation cohort (n = 101) and explore the longitudinal evolution of CRP during anti PD-(L)1 treatment and the potential impact of dynamic CRP changes on treatment response and disease outcome in the discovery cohort. Joint models were implemented to evaluate the association of longitudinal CRP trajectories and progression risk. Primary treatment outcomes were progression-free survival (PFS) and overall survival (OS), while the objective response rate (ORR) was a secondary outcome, respectively. In the discovery cohort, elevated pretreatment CRP levels emerged as independent predictors of worse PFS (HR per doubling of baseline CRP = 1.37, 95% CI: 1.16-1.63, p < 0.0001), worse OS (HR per doubling of baseline CRP = 1.42, 95% CI: 1.18-1.71, p < 0.0001) and a lower ORR ((odds ratio (OR) of ORR per doubling of baseline CRP = 0.68, 95% CI: 0.51-0.92, p = 0.013)). In the validation cohort, pretreatment CRP could be fully confirmed as a predictor of PFS and OS, but not ORR. Elevated trajectories of CRP during anti PD-(L)1 treatment (adjusted HR per 10 mg/L increase in CRP = 1.22, 95% CI: 1.15-1.30, p < 0.0001), as well as a faster increases of CRP over time (HR per 10 mg/L/month faster increase in CRP levels = 13.26, 95% CI: 1.14-154.54, p = 0.039) were strong predictors of an elevated progression risk, whereas an early decline of CRP was significantly associated with a reduction in PFS risk (HR = 0.91, 95% CI: 0.83-0.99, p = 0.036), respectively. These findings support the concept that CRP should be further explored by future prospective studies as a simple non-invasive biomarker for assessing treatment benefit during anti PD-(L)1 treatment in advanced NSCLC.

Find related publications in this database (Keywords)

C-reactive protein

immune checkpoint inhibition

biomarker

treatment response

joint model

© Med Uni Graz • Impressum